See the published version of this preprint at The Journal of Headache and Pain.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Dagny Holle-Lee
University of Duisburg-Essen, University Hospital Essen
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4872-0384
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are not available, yet, although many patients treated with CGRP mAB under real world conditions can be considered as highly therapy-refractory.
Methods: Clinical routine data of highly therapy-refractory migraine patients treated with erenumab 70mg for three months between November 2018 and December 2019 in the West German Headache Center, University Hospital Essen, Germany, were analysed. Monthly migraine days (MMD), monthly headache days (MHD) and days of acute medication intake (AMD) were assessed. Statistical analysis was performed using the Wilcoxon test. Descriptive statistics were performed to evaluate changes of vegetative symptoms, acute medication response, side effects, as well as treatment satisfaction.
Results: Complete clinical data were available for 26 episodic (EM) and 74 chronic (CM) migraineurs. Sixty-six % (n=49) of CM patients had an additional medication overuse headache (MOH). After three months 57.7 % of EM patients and 41.9 % of CM patients had a 50% or greater reduction of MMD. The mean number of MMD was reduced by 3.43 (SE 1.26) in EM, and by 4.72 (SE 0.87) in CM. Thirty-nine patients (52.7%) returned from chronic to episodic course of migraine. After three months, 23 patients (46.9%) were not suffering from a MOH anymore.
Conclusions: Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients.
Trial registration: Retrospective registered.
Keywords
migraine, erenumab, therapy, real-world, CGRP antibody
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at The Journal of Headache and Pain.
No community comments so far
Editor assigned
On 17 Jun, 2020
Editorial decision: Accept
On 17 Jun, 2020
Submission checks complete
On 16 Jun, 2020
Editor invited
On 16 Jun, 2020
Version 3
Posted 12 Jun, 2020
No comments provided
Editor assigned
On 09 Jun, 2020
Editorial decision: Minor revision
On 09 Jun, 2020
Submission checks complete
On 08 Jun, 2020
Editor invited
On 08 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 31 May, 2020
Review #1 received
Received 22 May, 2020
Reviewer #1 agreed
On 19 May, 2020
Editor assigned
On 15 May, 2020
Reviewers invited
Invitations sent on 15 May, 2020
Submission checks complete
On 14 May, 2020
Editor invited
On 14 May, 2020
No comments provided
Review #2 received
Received 14 Apr, 2020
Editorial decision: Major revision
On 14 Apr, 2020
Review #1 received
Received 13 Apr, 2020
Reviewer #2 agreed
On 03 Apr, 2020
Reviewers invited
Invitations sent on 01 Apr, 2020
Reviewer #1 agreed
On 01 Apr, 2020
Editor assigned
On 31 Mar, 2020
Submission checks complete
On 30 Mar, 2020
Editor invited
On 30 Mar, 2020
First submitted
On 26 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at The Journal of Headache and Pain.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Dagny Holle-Lee
University of Duisburg-Essen, University Hospital Essen
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4872-0384
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at The Journal of Headache and Pain.
No community comments so far
Editor assigned
On 17 Jun, 2020
Editorial decision: Accept
On 17 Jun, 2020
Submission checks complete
On 16 Jun, 2020
Editor invited
On 16 Jun, 2020
Version 3
Posted 12 Jun, 2020
No comments provided
Editor assigned
On 09 Jun, 2020
Editorial decision: Minor revision
On 09 Jun, 2020
Submission checks complete
On 08 Jun, 2020
Editor invited
On 08 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 31 May, 2020
Review #1 received
Received 22 May, 2020
Reviewer #1 agreed
On 19 May, 2020
Editor assigned
On 15 May, 2020
Reviewers invited
Invitations sent on 15 May, 2020
Submission checks complete
On 14 May, 2020
Editor invited
On 14 May, 2020
No comments provided
Review #2 received
Received 14 Apr, 2020
Editorial decision: Major revision
On 14 Apr, 2020
Review #1 received
Received 13 Apr, 2020
Reviewer #2 agreed
On 03 Apr, 2020
Reviewers invited
Invitations sent on 01 Apr, 2020
Reviewer #1 agreed
On 01 Apr, 2020
Editor assigned
On 31 Mar, 2020
Submission checks complete
On 30 Mar, 2020
Editor invited
On 30 Mar, 2020
First submitted
On 26 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at The Journal of Headache and Pain.
Background: Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are not available, yet, although many patients treated with CGRP mAB under real world conditions can be considered as highly therapy-refractory.
Methods: Clinical routine data of highly therapy-refractory migraine patients treated with erenumab 70mg for three months between November 2018 and December 2019 in the West German Headache Center, University Hospital Essen, Germany, were analysed. Monthly migraine days (MMD), monthly headache days (MHD) and days of acute medication intake (AMD) were assessed. Statistical analysis was performed using the Wilcoxon test. Descriptive statistics were performed to evaluate changes of vegetative symptoms, acute medication response, side effects, as well as treatment satisfaction.
Results: Complete clinical data were available for 26 episodic (EM) and 74 chronic (CM) migraineurs. Sixty-six % (n=49) of CM patients had an additional medication overuse headache (MOH). After three months 57.7 % of EM patients and 41.9 % of CM patients had a 50% or greater reduction of MMD. The mean number of MMD was reduced by 3.43 (SE 1.26) in EM, and by 4.72 (SE 0.87) in CM. Thirty-nine patients (52.7%) returned from chronic to episodic course of migraine. After three months, 23 patients (46.9%) were not suffering from a MOH anymore.
Conclusions: Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients.
Trial registration: Retrospective registered.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...